Reglan Tardive Dyskinesia Attorney: Washington Reglan Tardive Dyskinesia Injury Lawyer

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

Can I sue for tardive dyskinesia caused by Reglan in Washington

If you developed tardive dyskinesia from Reglan (metoclopramide), you may have legal options. The FDA requires a boxed warning about this risk. Washington law allows product liability claims. Consult a qualified attorney to discuss your case and potential compensation for medical costs and suffering.

From General Health Awareness to Medication-Related Injury

For decades, public health communication has centered on broad wellness principles, emphasizing preventive care and the management of common conditions. This foundational approach has served to educate communities on maintaining general health, from nutrition to routine medical screenings. Within this framework, pharmaceutical interventions have been presented as tools for symptom relief and disease management, with their benefits often highlighted in patient education materials. As medical knowledge has advanced, the focus has necessarily shifted toward understanding the long-term implications of specific treatments. One area of growing attention involves the neurological effects associated with certain medications, particularly when used over extended periods. In the context of mass production and widespread prescription, the potential for adverse outcomes becomes a matter of public health significance. This transition from general health awareness to occupational exposure concern emerges when considering the legal and medical dimensions of medication-related injuries. For individuals who have been prescribed drugs like Reglan, the risk of developing movement disorders such as tardive dyskinesia represents a serious health consequence. The question of liability and compensation arises when these injuries occur, prompting affected individuals to seek legal counsel. In Washington, those harmed by Reglan exposure may consult with a tardive dyskinesia attorney to explore their options, marking a pivot from general health education to specific legal recourse for occupational or iatrogenic harm.

Understanding Reglan and Its Link to Tardive Dyskinesia

Reglan (metoclopramide) is a dopamine D2-receptor blocking agent prescribed primarily for nausea, vomiting, and gastroparesis. Its use carries a well-documented risk of tardive dyskinesia (TD), a potentially irreversible movement disorder characterized by involuntary, repetitive movements of the face, tongue, trunk, and limbs. The clinical presentation of TD can include grimacing, lip smacking, rapid eye blinking, and jerking motions of the extremities. Diagnosis is based on a history of exposure to a dopamine-blocking agent, such as Reglan, and the presence of characteristic dyskinetic movements after excluding other causes (https://pubmed.ncbi.nlm.nih.gov/34712535/). The condition may develop after short-term or long-term use, and its severity can range from mild to disabling. The pharmacological mechanism linking Reglan to TD involves its action as a dopamine D2-receptor antagonist. By blocking dopamine receptors in the brain's basal ganglia, metoclopramide can disrupt normal motor control pathways, leading to extrapyramidal side effects. Over time, this blockade may cause supersensitivity of dopamine receptors, contributing to the development of TD (https://pubmed.ncbi.nlm.nih.gov/34712535/). The risk of TD increases with longer duration of treatment and higher cumulative dosages, as noted in the FDA-approved labeling (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Even a single dose of metoclopramide has been reported to trigger TD in susceptible individuals, particularly those with underlying risk factors such as advanced age, female sex, or a history of psychiatric disorders (https://pubmed.ncbi.nlm.nih.gov/34712535/).

FDA Warnings and Legal Implications for Washington Patients

The FDA has issued a boxed warning for Reglan, emphasizing that it can cause TD, a potentially irreversible serious movement disorder. The warning states that the risk increases with duration of treatment and total cumulative dosage, and it advises using Reglan for the shortest duration necessary, with periodic reassessment of the need for continued therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic gastroesophageal reflux, the maximum treatment duration is 12 weeks, and for those with diabetic gastroparesis, treatment should not exceed 12 weeks unless unavoidable, in which case monitoring for TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and immediate discontinuation is required if signs or symptoms of TD develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these warnings, questions have been raised about the adequacy of risk communication to patients and healthcare providers. A medicolegal analysis highlights that physicians may face liability if they fail to warn patients about the risk of TD associated with Reglan, particularly when they have knowledge of these adverse effects (https://pubmed.ncbi.nlm.nih.gov/31356297/). Pharmaceutical companies may also be held liable for inadequate warnings regarding side effects such as TD (https://pubmed.ncbi.nlm.nih.gov/31356297/). For affected patients, legal considerations include the need to document the timeline of Reglan exposure and the onset of TD symptoms, as well as to identify any failure to monitor or discontinue the drug appropriately. The timeline between Reglan exposure and documented harm can vary widely. While TD typically develops after months or years of treatment, cases have been reported after a single dose, as seen in a postoperative gynecological patient who developed dyskinetic movements following intraoperative administration of metoclopramide (https://pubmed.ncbi.nlm.nih.gov/34712535/). This variability underscores the importance of individualized risk assessment and close monitoring. Patients who develop TD may experience persistent symptoms even after Reglan is discontinued, and treatment options are limited, often focusing on symptom management rather than reversal. For individuals in Washington who have developed TD after using Reglan, consulting with an attorney experienced in pharmaceutical injury cases may be advisable. Legal claims may center on inadequate warnings, failure to monitor, or negligence in prescribing practices. Evidence of the drug's known risks, as documented in FDA labeling and medical literature, can support such claims. The boxed warning explicitly states that Reglan can cause TD and that the risk increases with longer use, providing a clear basis for evaluating whether proper precautions were taken (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In summary, Reglan use is associated with a significant risk of TD, a potentially irreversible movement disorder. The FDA has mandated strong warnings, but questions about the adequacy of risk communication persist. Patients and healthcare providers should be vigilant about monitoring for early signs of TD, using the drug for the shortest possible duration, and discontinuing it immediately if symptoms appear. Legal recourse may be available for those harmed by inadequate warnings or improper prescribing practices.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is tardive dyskinesia and how is it related to Reglan?

Tardive dyskinesia (TD) is a potentially irreversible movement disorder characterized by involuntary, repetitive movements of the face, tongue, trunk, and limbs. It is caused by prolonged use of dopamine-blocking agents like Reglan (metoclopramide). The risk increases with longer treatment duration and higher cumulative doses. Even a single dose can trigger TD in susceptible individuals (https://pubmed.ncbi.nlm.nih.gov/34712535/).

What are the FDA warnings about Reglan and tardive dyskinesia?

The FDA has issued a boxed warning for Reglan stating that it can cause tardive dyskinesia, a potentially irreversible serious movement disorder. The warning advises using Reglan for the shortest duration necessary, with periodic reassessment. For gastroesophageal reflux, treatment should not exceed 12 weeks; for diabetic gastroparesis, it should also be limited to 12 weeks unless unavoidable (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Can I file a lawsuit if I developed tardive dyskinesia from Reglan in Washington?

Yes, individuals in Washington who developed tardive dyskinesia after using Reglan may have legal recourse. Claims may be based on inadequate warnings, failure to monitor, or negligence in prescribing. Consulting with an attorney experienced in pharmaceutical injury cases is advisable to evaluate the specific circumstances and evidence, including FDA labeling and medical literature (https://pubmed.ncbi.nlm.nih.gov/31356297/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.